论文部分内容阅读
一、应用 C100-3抗体蛋白的测定技术现有 Ortho 公司、Dainabct 公司出品的 EIA 法和大塚公司出品的 RIA 法3个系列,其质量性能基本相同,惟 Ortho 产品的非特异性阳性率似稍高,但尚须确认。研究 HCV 抗体量与 OD 值发现,有显示定量反应的范围。表现为慢丙肝的抗体量最高,但随着肝病变的进展而渐形降低。由此推测,继行随访追踪检查必可发现阴转病例。同时发现,在病程经过的变动中,抗体是随 ALT 的消长而降升,因而可用以观察疗效,惟就强力宁治疗例的观察,发
First, the application of C100-3 antibody protein measurement technology Ortho company, Dainabct companies produced EIA and Otsuka RIA produced three series, the quality of performance is basically the same, but Ortho products non-specific positive rate was slightly higher , But still need to confirm. The study of HCV antibody levels and OD values was found, showing a range of quantitative responses. Antibodies showed the highest amount of hepatitis C, but gradually decreased with the progress of liver disease. From this speculation, follow-up follow-up follow-up inspection can be found in cases of negative conversion. Also found that changes in the course of the disease, the antibody decreases with the rise and fall of ALT, which can be used to observe the effect, but the treatment of strong Ning rather observation, hair